0000000000535188

AUTHOR

Axel Hinke

showing 3 related works from this author

The role of surgery in patients with primary metastatic breast cancer (PMBC) receiving monoclonal antibody treatment.

2014

1097 Background: Apart from the individual palliative need, the beneficial effect of surgically removing the primary tumor in PMBC on long-term outcomes, as suggested by retrospective series and me...

OncologyCancer Researchmedicine.medical_specialtyPrimary (chemistry)medicine.drug_classbusiness.industryMonoclonal antibodymedicine.diseaseMetastatic breast cancerPrimary tumorhumanitiesOncologyInternal medicinemedicineIn patientbusinessJournal of Clinical Oncology
researchProduct

Trastuzumab treatment in patients with advanced breast cancer (ABC) confined to locoregional and skeletal sites: Results from a large nonintervention…

2012

640 Background: In a prospective observation study routine trastuzumab (T) treatment in HER2+ ABC was evaluated in a total of 1,687 patients (pts) since 2001. This large number allows the subgroup analysis of patients with the involvement of specific sites. Methods: Information on extent of advanced disease was available in 1,674 pts (99%) with HER2 overexpressing ABC. Pts were either pre-treated (39%) or naïve to palliative chemotherapy (CT). The following subgroups and their characteristics were analysed: I: locally ABC only; II: bone metastases allowing for concomitant local tumour; III: other. Results: Locally advanced lesions were found to be the sole BC manifestation in 145 pts (8.7%…

OncologyCancer Researchmedicine.medical_specialtybusiness.industryAdvanced breastCancermedicine.diseaseSurgeryOncologyTrastuzumabInternal medicinemedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK …

2013

Background: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer. Methods: Two dose levels (I/II) were defined: capecitabine 850/1000 mg m−2 twice daily on days 1–14; oxaliplatin 100/130 mg m−2 on day 1; bevacizumab 7.5 mg kg−1 on day 1; imatinib 300 mg day−1 on days 1–21 every 21 days. The primary study endpo…

OncologysafetyAdultMaleCancer Researchmedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentcolorectal cancerbevacizumabAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalDrug Administration SchedulePiperazinesCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesCapecitabineAgedAged 80 and overChemotherapybusiness.industrySunitiniboxaliplatinMiddle Agedmedicine.diseaseSurgeryOxaliplatinImatinib mesylatePyrimidinesTreatment OutcomeOncologyimatinibFluorouracilBenzamidesClinical StudyImatinib MesylateFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish Journal of Cancer
researchProduct